Sticking With This Ocular Therapeutix Price Target as Key Treatment Moves Forward
The small-cap healthcare firm offered some encouraging earnings results.
The small-cap healthcare firm offered some encouraging earnings results.
Locking in a nice double-digit gain and rebuilding cash along the way.
Several insiders purchased just over 180,000 shares in total during mid-May, always a nice vote of confidence.
There is a relief bounce on an in-line CPI report, but the inflation issue isn’t going away.
Let’s scan through the headlines for the stories of the week that speak to our Pro Portfolio holdings.
I’m looking for hidden gems like this cancer treatment play following earnings.